PLRX Pliant Therapeutics, Inc. Stock Quote

PLRX [NASD]

Index	-	P/E	-	EPS (ttm)	-2.85	Insider Own	8.96%	Shs Outstand	36.12M	Perf Week	8.68%
Market Cap	195.99M	Forward P/E	-	EPS next Y	-3.59	Insider Trans	0.00%	Shs Float	32.93M	Perf Month	-25.18%
Income	-102.50M	PEG	-	EPS next Q	-0.81	Inst Own	89.00%	Short Float	9.62%	Perf Quarter	-37.53%
Sales	6.60M	P/S	29.70	EPS this Y	-39.40%	Inst Trans	3.22%	Short Ratio	17.22	Perf Half Y	-63.24%
Book/sh	4.81	P/B	1.09	EPS next Y	-8.80%	ROA	-45.20%	Target Price	39.67	Perf Year	-81.90%
Cash/sh	4.78	P/C	1.10	EPS next 5Y	-	ROE	-49.00%	52W Range	3.96 - 33.95	Perf YTD	-61.04%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-47.30%	52W High	-84.51%	Beta	-
Dividend %	-	Quick Ratio	10.10	Sales past 5Y	-	Gross Margin	-	52W Low	32.66%	ATR	0.49
Employees	91	Current Ratio	10.10	Sales Q/Q	-45.50%	Oper. Margin	-	RSI (14)	45.70	Volatility	9.07% 10.52%
Optionable	Yes	Debt/Eq	0.04	EPS Q/Q	-21.30%	Profit Margin	-	Rel Volume	1.26	Prev Close	4.93
Shortable	Yes	LT Debt/Eq	0.03	Earnings	May 09 AMC	Payout	-	Avg Volume	183.96K	Price	5.26
Recom	1.70	SMA20	2.18%	SMA50	-18.64%	SMA200	-58.95%	Volume	231,456	Change	6.69%

May-25-22

Initiated

Cantor Fitzgerald

Overweight

$28

Dec-10-21

Initiated

Oppenheimer

Outperform

$40

Nov-24-21

Initiated

RBC Capital Mkts

Outperform

$38

Nov-03-21

Initiated

H.C. Wainwright

Buy

$45

Apr-20-21

Initiated

BTIG Research

Buy

$51

Apr-05-21

Initiated

Citigroup

Buy

$52

Jun-29-20

Initiated

Piper Sandler

Overweight

$50

Jun-29-20

Initiated

Needham

Buy

$40

Jun-29-20

Initiated

Cowen

Outperform

Jun-29-20

Initiated

Citigroup

Buy

$40

May-18-22 11:15AM	Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference GlobeNewswire
May-11-22 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire -11.99%
May-09-22 05:25PM	Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Lags Revenue Estimates Zacks -10.98%
04:05PM	Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results GlobeNewswire
06:28AM	Will Pliant Therapeutics (NASDAQ:PLRX) Spend Its Cash Wisely? Simply Wall St.
May-05-22 06:25PM	CytomX Therapeutics (CTMX) Reports Q1 Loss, Lags Revenue Estimates Zacks
08:00AM	Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809 GlobeNewswire
May-03-22 08:00AM	Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis GlobeNewswire
May-02-22 08:00AM	Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference GlobeNewswire
Apr-13-22 02:24PM	Read Why Pliant Therapeutics Shares Are Soaring Today Benzinga +8.30%
Apr-08-22 08:44AM	Do Institutions Own Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares? Simply Wall St.
Apr-05-22 08:03AM	Pliant Therapeutics to Participate in Needham Healthcare Conference GlobeNewswire
Feb-28-22 07:43PM	CORRECTION - Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire -7.05%
05:55PM	Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire
08:00AM	Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF- Signaling in Healthy Volunteers GlobeNewswire
Feb-24-22 05:41PM	Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis GlobeNewswire
08:03AM	Pliant Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Feb-07-22 12:10PM	Pliant Therapeutics (NASDAQ:PLRX) investors are sitting on a loss of 69% if they invested a year ago Simply Wall St.
Jan-11-22 08:03AM	Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones GlobeNewswire +11.11%
Dec-21-21 08:06AM	Pliant Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-13-21 07:37PM	Oppenheimer Bets on These 2 Strong Buy Stocks; Sees at Least 90% Upside TipRanks
Nov-30-21 05:24AM	10 Pharmaceutical Stocks to Buy Under $20 According to Jeremy Greens Redmile Group Insider Monkey
Nov-18-21 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-10-21 10:32AM	Pliant Therapeutics, Inc. (PLRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? Zacks
Nov-09-21 06:35PM	Pliant Therapeutics, Inc. (PLRX) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:06PM	Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results GlobeNewswire
10:26AM	We're Not Very Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate Simply Wall St.
Oct-07-21 08:06AM	Pliant Therapeutics to Participate in Piper Sandler Lung Day GlobeNewswire
Sep-07-21 12:12PM	Mid-Day Market Update: Gold Drops 2%; Pliant Therapeutics Shares Jump Benzinga
12:07PM	Why Pliant Therapeutics Stock Is Surging Today Motley Fool
07:21AM	Pliant Stock Moves Higher On Positive Data From Pulmonary Fibrosis Trial Benzinga
07:00AM	Pliant Therapeutics Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis GlobeNewswire
Sep-03-21 04:10PM	Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis GlobeNewswire
Sep-02-21 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire +7.21%
Aug-11-21 06:44AM	Shareholders in Pliant Therapeutics (NASDAQ:PLRX) are in the red if they invested a year ago Simply Wall St.
Aug-09-21 04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results GlobeNewswire
Aug-03-21 08:00AM	Pliant Therapeutics to Participate in the BTIG Biotechnology Conference GlobeNewswire
May-13-21 02:30AM	Analysts Are Upgrading Pliant Therapeutics, Inc. (NASDAQ:PLRX) After Its Latest Results Simply Wall St. -6.10%
May-10-21 04:21PM	Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results GlobeNewswire -7.33%
May-05-21 08:05AM	Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference GlobeNewswire -6.64%
Apr-05-21 08:00AM	Pliant Therapeutics to Participate in Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-22-21 08:54AM	We're Not Very Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate Simply Wall St.
Mar-16-21 04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
08:00AM	Pliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner GlobeNewswire
Feb-18-21 08:30AM	Pliant Therapeutics to Participate in Upcoming Virtual Investor Events GlobeNewswire -5.00%
Feb-17-21 09:00AM	Creating More Affordable Homes for Families in Red Lake CNW Group
Feb-09-21 08:52AM	Sasol reuses wax from spent catalysts as part of commitment to responsible production and consumption PR Newswire
07:45AM	Sasol reuses wax from spent catalysts as part of commitment to responsible production and consumption PR Newswire
Jan-12-21 08:00AM	Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors GlobeNewswire
Jan-04-21 08:00AM	Pliant Therapeutics Announces Appointment of Gregory P. Cosgrove, M.D., FCCP, as Vice President of Clinical Development, IPF GlobeNewswire +7.92%
Dec-11-20 12:54PM	Is PLRX A Good Stock To Buy Now? Insider Monkey
Dec-02-20 03:28AM	With A 6.5% Return On Equity, Is Pliant Therapeutics, Inc. (NASDAQ:PLRX) A Quality Stock? Simply Wall St. -5.00%
Nov-19-20 08:00AM	Pliant Therapeutics To Participate In The Piper Sandler 32nd Annual Virtual Healthcare Conference PR Newswire
Nov-10-20 04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results PR Newswire
Nov-09-20 08:00AM	Pliant Therapeutics to Present Data at The Liver Meeting® 2020 PR Newswire
Oct-05-20 08:00AM	Pliant Therapeutics Appoints Mike Ouimette as General Counsel PR Newswire +6.67%
Sep-24-20 08:00AM	Pliant Therapeutics Presents Data at American Thoracic Society 2020 Virtual Sessions PR Newswire
Sep-04-20 08:00AM	Pliant Therapeutics To Participate In Upcoming Virtual Investor Conferences PR Newswire
Sep-03-20 12:28PM	What Type Of Shareholders Make Up Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) Share Registry? Simply Wall St.
Aug-27-20 06:00AM	Pliant Therapeutics Presents Data at The Digital International Liver Congress 2020 PR Newswire
Aug-11-20 04:05PM	Pliant Therapeutics Provides Corporate Update and Announces Second-Quarter 2020 Financial Results PR Newswire
Jun-13-20 07:01AM	Could This Recent IPO Biotech Become the Next Moderna? Motley Fool
Jun-05-20 04:05PM	Pliant Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares PR Newswire
Jun-04-20 08:13AM	The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic Benzinga +9.67%
Jun-03-20 03:54PM	Warner Music Shares Rise After $1.9 Billion Upsized U.S. IPO Bloomberg
11:40AM	Pliant Therapeutics shares soar 55% in trading debut MarketWatch
07:35AM	Pliant Therapeutics prices IPO at $16 to raise $144 million MarketWatch
Jun-02-20 09:56PM	Pliant Therapeutics Announces Pricing of Initial Public Offering PR Newswire
03:46PM	IPOs Revive With Warner Music Kicking Off $6.4 Billion Week Bloomberg
06:53AM	Pliant Therapeutics increases size of planned IPO to 9 million shares from 6 million MarketWatch

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cummings Keith Lamont	Chief Financial Officer	Sep 03	Option Exercise	2.08	20,000	41,600	67,621	Sep 03 06:27 PM
Lefebvre Eric	Chief Medical Officer	Jun 18	Sale	28.87	12,500	360,821	137,080	Jun 22 07:52 PM
Coulie Bernard	President and CEO	Jun 14	Sale	33.03	4,000	132,102	449,317	Jun 15 08:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience